No adjuvant therapy

OTHER4 trials

Sponsors

Hospital JP Garrahan, The Central and Eastern European Gynecologic Oncology Group, Fudan University, Ningbo No. 1 Hospital

Conditions

Cervical CancerEGFR Gene MutationHypoglycemiaLung CancerMinimal Residual DiseaseUnilateral Retinoblastoma

Phase 3

Treatment Protocol for Non-Metastatic Unilateral Retinoblastoma

CompletedNCT03475121

Hospital JP GarrahanUnilateral Retinoblastoma

Start: 2018-01-01End: 2025-03-28Updated: 2025-04-13

Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy

RecruitingNCT04989647

The Central and Eastern European Gynecologic Oncology GroupCervical Cancer

Start: 2022-06-10End: 2032-12-31Target: 514Updated: 2023-09-07

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Not yet recruitingNCT06323148

Fudan UniversityEGFR Gene Mutation, Lung Cancer, Minimal Residual Disease

Start: 2024-04-01End: 2029-03-31Target: 226Updated: 2024-03-21

Unknown Phase

The Construction and Validation of a Risk Prediction Model for Perioperative Hypoglycemia in Digestive Endoscopy

CompletedNCT07132476

Ningbo No. 1 HospitalHypoglycemia

Start: 2024-01-01End: 2024-06-30Updated: 2025-08-20

Related Papers

Development and validation of a novel nomogram incorporating psychosocial factors for predicting hypoglycemia during perioperative period of digestive endoscopy (DREAM-Hypo Model).

2025-10-16

CERVANTES: an international randomized trial of radical surgery followed by adjuvant (chemo) radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer (CEEGOG-CX-05; ENGOT-CX16).

2022-10-0327 citations